User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

Congress report: EuroPCR, 2012

Congress report: EuroPCR, 2012
  • Cardiometabolic
  • Hypertension


Resource type



EuroPCR 2012
Transcatheter Aortic Valve Implantation
Renal denervation
Biodegradable Stents
coronary artery disease
Optimal medical therapy (OMT)
Percutaneous coronary intervention (PCI)
Congress report

Prof Omar Awwad reports from Euro PCR 2012, the Official Congress of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Transcatheter Aortic Valve Implantation (TAVI)

There were many studies and presentations on the Transcatheter Aortic Valve Implantation (TAVI) procedure for Aortic Valve (AV) intervention at this year’s Euro PCR meeting. Among the highlights, a study of TAVI for treating surgical valve failure showed a high rate of survival at one year but concluded that the valve-in-valve procedure, although feasible, is technically demanding and raises several safety concerns.

The Source XT Registry of observational data on the next generation TAVI device now has early data from high risk patients showing that the Sapien XT™ valve (Edwards Life Sciences) is safe using either a transapical or a transfemoral access approach. 

A real-world study of the rate of strokes in patients with new TAVI devices showed that the rate of stroke following TAVI is likely not as high as the PARTNER A trial first suggested, and a refined understanding of just when and how strokes occur should help bring rates down even further.

Renal denervation systems

The Symplicity™ System (Medtronic) is leading the way in renal denervation systems, having demonstrated average reductions in office-based blood pressure (BP) of 32/12 mmHg at 6 months in the SYMPLICITY Hypertension Trial. In the same trial, 84% of patients had a >10 mmHg drop in systolic BP from baseline.

Heading up the rest of the pack is the EnligHTN System. St. Jude's announced Confirmité Europeén (CE Mark) approval and launch of EnligHTN during the opening of the Euro PCR meeting. The possibility of a persistent treatment effect using a procedure that helps severe hypertension patients, and may even offer a cure for hypertension in the future, is very exciting indeed.

Biodegradable Stents

The COMFORTABLE AMI Study suggests that the use of Bioerodable Polymer, Biolimus-eluting stents (BES) in patients with ST elevation MI (myocardial infarction) (STEMI) can radically reduce the rate of major adverse cardiac events (MACE) at one year.  It is estimated that only 24 patients would need to be treated with BES to avoid one major event.  The major driver of this benefit was a reduction in both target vessel reinfarction and target lesion revascularization.

The COMPARE II trial found that the next generation Nobari® BES (Terumo) is non inferior to the market leading everolimus-eluting stents (EES; Xience V, Prime Promus) at one year. At 12 month follow up, there is no signal that the device, which boasts a Bioerodable Polymer, is any safer than the stents that use a permanent polymer coating.

The FAME II study

Patients with stable coronary artery disease (CAD) in whom fractional flow reserve (FFR) identifies at least one hemodynamically-significant stenosis face a more than 10 times higher risk of urgent revascularization if they are initially treated with optical medical therapy (OMT) rather than percutaneous coronary intervention (PCI). The new findings should help physicians identify which stable CAD patients will do better with PCI than OMT and vice versa.

Terms of use

This is a copyrighted resource for the sole purpose of education. Resource may be used for classroom training only and must remain as is, including the branding and EXCEMED logo. It is backed by a publishing license, signed by the author.